NCT04681105 - Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 18, 2020

Primary Completion Date

May 5, 2026

Study Completion Date

May 5, 2026

Conditions

Recurrent Acute LeukemiaRecurrent B Acute Lymphoblastic LeukemiaRecurrent Blastic Plasmacytoid Dendritic Cell NeoplasmRecurrent Chronic Myelogenous Leukemia, BCR-ABL1 PositiveRecurrent Hairy Cell LeukemiaRecurrent Hematologic MalignancyRecurrent Hodgkin LymphomaRecurrent T Acute Lymphoblastic LeukemiaRefractory Acute LeukemiaRefractory B Acute Lymphoblastic LeukemiaRefractory Blastic Plasmacytoid Dendritic Cell NeoplasmRefractory Chronic Myelogenous Leukemia, BCR-ABL1 PositiveRefractory Hairy Cell LeukemiaRefractory Hematologic MalignancyRefractory Hodgkin LymphomaRefractory T Acute Lymphoblastic LeukemiaSystemic Mastocytosis

Interventions

DRUG

Acetaminophen

Given PO

DRUG

Dexamethasone

Given IV

DRUG

Diphenhydramine

Given IV or PO

BIOLOGICAL

Flotetuzumab

Given IV

DRUG

Ibuprofen

Given PO

DRUG

Ranitidine

Given IV

Trial Locations (1)

91010

City of Hope Medical Center, Duarte

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER